Dr. Scott Gottlieb, the new Commissioner of the Food & Drug Administration, has a big job and a lot of opinions. To say that Gottlieb has been outspoken in his criticism of the agency is a dramatic understatement. Indeed, he has written literally scores of columns and policy papers that, in tone and substance, fall somewhere between severe criticism and outright excoriation of FDA policy and practice. Among the cornucopia of policy issues is whether the FDA should loosen limits on communicating so-called “off label” medical and scientific information. Since the late 1990s, the FDA has done its very best to ignore the implications of these holdings and go about its business limiting speech.

Source: Forbes June 10, 2017 14:03 UTC